CTMX · CytomX Therapeutics, Inc.

Track CTMX — free

$2.72 -0.03 (-1.09%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$598.13M

217.90M

Volume · Sep 30 3.22M Avg daily vol (3M) 3.49M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$18.30M

Trailing 12 months

Net income (TTM)

−$79.65M

Trailing 12 months

Revenue growth YoY

-92.4%

Year over year

Operating margin

-476.2%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+69.6%

Year over year · more shares

Price change (1Y)

-14.9%

Trailing year

Short interest

17.7%

Latest settlement · 9.3 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. CytomX broadened the Varseta-M program, initiating new monotherapy expansion cohorts in gastric/GEJ, PDAC and BTC cancers, advancing combination studies aimed at earlier-line CRC, and reaffirming a 1H 2027 registrational start, while Q2 revenue collapsed to $1.4M from $18.7M on collaboration roll-offs, driving a wider operating loss despite a $330.3M cash balance expected to fund the company into 2H 2028.

Bullish

+ Varseta-M Phase 1 monotherapy enrollment complete at 113 patients, with Phase 1 data update expected by year-end 2026 to inform a registrational study planned for 1H 2027.
+ Varseta-M development expanded into three additional GI cancers (gastric/GEJ, PDAC, BTC), with ~20-patient Phase 1 monotherapy expansion cohorts initiating Q3 2026.
+ New Phase 1/2 Varseta-M chemo combination study in 2L mCRC planned to start in Q4 2026 to support replacing irinotecan in earlier-line CRC.
+ Cash runway extends to at least 2H 2028, supporting registrational and combination investment.
+ Prior reported preliminary PFS of 6.8–7.1 months at the 8.6/10 mg/kg optimization doses supports outlook against late-line benchmarks.

Bearish

− Q2 revenue fell to $1.4M from $18.7M year-over-year as BMS and Astellas collaborations wound down.
− Operating expenses rose to $25.2M from $19.9M year-over-year, driven by higher R&D ($17.6M vs $13.3M) on Varseta-M manufacturing and headcount.
− Registrational path remains unconfirmed between 3L and 4L, with FDA interactions and pivotal design still pending.
− Grade 3 diarrhea tolerability risk flagged as gating factor for moving Varseta-M upstream.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −33%

below

Price vs 50-day avg −16%

below

RSI (14) 37

neutral

MACD trend Negative

52-week position 1%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −26%

trailing

6-month return −36%

trailing

YTD return −36%

this year

Relative strength −48%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +46 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

17.73% of float · ▲ +15.3% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

179 holders — near 3-yr high, broad support

Squeeze score 79

high risk · 0–100

Fundamentals

Weak

Revenue growth −45%

Y/Y

Free cash flow $-75.8M

Balance sheet $61.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 88%

annualized · 1-yr

Max drawdown −60%

past year

ATR 6.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−33% Bearish

Price vs 50-day avg

−16% Bearish

RSI (14)

37 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +46 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

17.73% of float · ▲ +15.3% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

179 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $3 · 1% Range high $7

vs 200-day avg -33% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CTMX CytomX Therapeutics, Inc. this stock	$598.13M	-36.2%	-44.8%	—	17.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

179

% held: 98.6%
Net QoQ: +17.4M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

151

View

Short & Settlement

Short Interest Rising

Shares short

38.6M

Days to cover: 9.3d
Change: +5.1M sh

View

Short Volume

Short vol %

55%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

136.0K

Value: $481.3K
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

42.9%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$76.2M

Net income (FY): $-17.4M

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 16

View

Proposed Sales

Value

$461.9K

Shares: 101.8K
Filed: Nov 6, 2025

View

Exempt Offerings

Offering

$30.0M

Filed: Aug 17, 2023

View

Earnings & Events

Earnings Calls

Last call

Sep 14, 2026

View

Performance

	5D	20D	120D	MTD	YTD
CTMX	-2.2%	-25.9%	-35.9%	-19.1%	-36.2%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-1.5%	-26.0%	-48.0%	-18.5%	-48.0%

Key facts CIK 1501989 CUSIP 23284F105 13F (30d) 3 filings 3 filers Visit website Investor relations

CTMX · CytomX Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance